Contact Us
  • Choose License Type

Inherent damage in vagus nerve that controls the movement of food through the digestive tract is a major cause of diabetic gastroparesis. Damage in the vagus nerve leads to malfunctioning of muscles of the stomach and intestines and the movement of food is slowed or stopped.

The global diabetic gastroparesis treatment market is estimated to account for US$ 3,069.8 Mn in terms of value in 2018 and is expected to reach US$ 4,252.2 Mn by the end of 2027.

Global Diabetic Gastroparesis Treatment Market: Drivers

Development of effective therapeutics for the treatment of diabetic gastroparesis is expected to propel growth of the global diabetic gastroparesis treatment market over the forecast period. For instance, according to research presented at Digestive Disease Week, a medical meetings by Healthcare Convention & Exhibitors Association (HCEA), in June 2019, Velusetrag, an oral, highly selective 5-hydroxytryptamine receptor 4 agonist, effectively reduced symptoms and gastric emptying in patients with diabetic or idiopathic gastroparesis.

Global Diabetic Gastroparesis Treatment Market: Opportunities 

Developments in endoscopic ultrasonography are expected to offer lucrative growth opportunities for players in the global diabetic gastroparesis treatment market. Injection of botulinum toxin with direct ultrasonographic visualization to the muscularis propria of the pyloric sphincter can be effective in the treatment of diabetic gastroparesis. Moreover, endoscopic transpyloric stent placement is also expected to aid in treatment of the disease.

Global Diabetic Gastroparesis Treatment Market: Restraints

The reported incidence of diabetic gastroparesis is very low worldwide as the symptoms are common with general nausea, vomiting, and gastroesophageal reflux disease. Furthermore, the use of non-prescription drugs for the treatment of the symptoms of the disease restricts diagnosis of stage 1 and stage 2 gastroparesis. Such factors are also expected to propel growth of the global diabetic gastroparesis market. 

Key Takeaways:

Drugs segment in the global diabetic gastroparesis treatment market was valued at US$ 1,924.5 Mn in 2018 and is expected to reach US$ 2,646.8 Mn by 2027 at a CAGR of 3.6% during the forecast period. Drugs are the first choice of treatment for any kind of ailment, and surgical options are often used when pharmacological treatment is not producing any results or the disease has become life threatening. Patients as well as physicians are expected to prefer treatments with drugs as first line therapy which is expected to support growth of the market.

The hospital pharmacies segment held dominant position in the global diabetic gastroparesis treatment market in 2018, accounting for 48.4% share in terms of value, followed by retail pharmacies and online pharmacies, respectively. Patients are expected to visit hospitals frequently for routine check-ups as well as to renew their prescriptions and later buy the medicines from hospital pharmacies. Moreover, in countries in Asia Pacific regions patients often buy medicines from hospital pharmacies itself. These factors are expected to support growth of the segment over the forecast period.

The Antiemetic Agents segment held dominant position in the global diabetic gastroparesis treatment market in 2018, accounting for 53.8% share in terms of value, followed by gastroprokinetic agents, and botulinum toxin, respectively. Factors such as widespread presence of cheaper generic antiemetic agents, easy availability of drugs in pharmacies, and large number of manufacturers is expected to support growth of the segment.

Market Trends

Gastric electrical stimulation can be used for the treatment of diabetic gastroparesis. For instance, in November 2019, researchers from University of Louisville reported that gastric electrical stimulation is beneficial for improving the treatment of diabetic gastroparesis.

Players in the market are focused on raising funds. For instance, in January 2018, Neurogastrx raised US$ 45 million for building its management team. The company’s drug candidate, NG-101, is designed for the treatment of gastroparesis.

Regulations

U.S.

Regulatory History

  • September 23, 1999: Granting of Humanitarian Use Device (HUD) designation for Enterra (HUD #990014)
  • March 30, 2000: Approval of Enterra HDE (H990014)
  • March 25, 2013: Approval to profit on the sale of Enterra

Device Distribution

  • FDASIA amended section 520(m) of the FD&C Act to allow devices with HDEs indicated for use in pediatric patients or a pediatric subpopulation to be sold for profit; the number of devices distributed in any calendar year cannot exceed the Annual Distribution Number (ADN) for each device. The ADN is defined as the number of devices reasonably needed to treat, diagnose, or cure a population of 4,000 individuals in the United States. The FDA has interpreted this to mean that the calculation of the ADN should be 4,000 multiplied by the number of devices reasonably necessary to treat an individual. For Enterra, one device is reasonably necessary to treat an individual, therefore the ADN for this device is 4,000. Annual distribution of Enterra has not yet exceeded the ADN

Global Diabetic Gastroparesis Treatment Market: Key Developments 

Major players operating in the global diabetic gastroparesis treatment market include, Janssen Global Services, LLC, Cardinal Health, Inc., Evoke Pharma, Inc., Salix Pharmaceuticals, Inc., Alfa Wassermann SPA, Abbott Laboratories, Medtronic Plc., C. R. Bard, Inc. (Becton, Dickinson and Company), Rhythm Pharmaceuticals, Inc., Boston Scientific Corporation, Kimberly-Clark Corporation, Vanda Pharmaceuticals, Inc., and Allergan, plc.

Global Diabetic Gastroparesis Treatment Market: Key Developments

January 2020: Evoke Pharma, Inc. collaborated with EVERSANA, a provider of commercial services to the life science industry, to utilize EVERSANA’s integrated suite of outsourced services to commercialize and distribute Gimoti, a nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis, in the U.S.

May 2019: Allergan, plc expanded the PLEDGE program with a fifth study that assesses relamorelin, an investigational, ghrelin agonist for the treatment of diabetic gastroparesis

Segmentation

  • By Product Type
    • Drugs
      • Gastroprokinetic Agents
      • Antiemetic Agents
      • Botulinum Toxin
    • Surgical Treatment Products
      • Gastric Electrical Stimulation (GES) Device
      • Percutaneous Endoscopic Gastrostomy (PEG) Kit
      • Parenteral Nutrition
    • By Disease Indication
      • Compensated Gastroparesis
      • Gastric Failure
    • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • By Region
      • North America
      • Latin America
      • Europe
      • Asia Pacific
      • Middle East
      • Africa
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner